{"nctId":"NCT00249769","briefTitle":"Determining Safety and Efficacy of Japanese Encephalitis Vaccine When Given With Measles Vaccine","startDateStruct":{"date":"2005-11-21","type":"ACTUAL"},"conditions":["Encephalitis, Japanese B"],"count":600,"armGroups":[{"label":"LJEV then MV","type":"EXPERIMENTAL","interventionNames":["Biological: Live Japanese encephalitis vaccine SA 14-14-2 (LJEV)","Biological: Measles Vaccine (MV)"]},{"label":"LJEV and MV","type":"EXPERIMENTAL","interventionNames":["Biological: Live Japanese encephalitis vaccine SA 14-14-2 (LJEV)","Biological: Measles Vaccine (MV)"]},{"label":"MV then LJEV","type":"EXPERIMENTAL","interventionNames":["Biological: Live Japanese encephalitis vaccine SA 14-14-2 (LJEV)","Biological: Measles Vaccine (MV)"]}],"interventions":[{"name":"Live Japanese encephalitis vaccine SA 14-14-2 (LJEV)","otherNames":[]},{"name":"Measles Vaccine (MV)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participant is healthy, aged between 8 months (± 2 weeks) at inclusion visit\n* Subject is a full-term infant\n* Subject's parents or legal guardian willing to provide signed informed consent.\n* Children have completed 3 doses each of diphtheria, tetanus, pertussis (DTP) and oral polio vaccine (OPV).\n\nExclusion Criteria:\n\n* History of documented HIV.\n* Known or suspected impairment of immunologic function.\n* History of serious chronic disease\n* Underlying medical condition such as inborn errors of metabolism, failure to thrive, bronchopulmonary dysplasia, or any major congenital abnormalities requiring surgery or chronic treatment.\n* Acute medical illness with or without fever within the last 72 hours or an axillary temperature ≥ 37.5°C at the time of inclusion.\n* History of documented suspected encephalitis, encephalopathy, or meningitis\n* History of measles\n* History of thrombocytopenic purpura.\n* Received any JE or measles vaccine prior to enrollment.\n* Received any vaccine, other than the study vaccines, within 2 weeks prior to or scheduled to receive a non-study vaccination during the conduct of this trial.\n* Hypotonic - hyporesponsiveness, after the preceding vaccination.\n* History of seizures, including history of febrile seizures, or any other neurologic disorder.\n* Prior or anticipated receipt of immune globulin or other blood products, or injected or oral corticosteroids or other immune modulator therapy except routine vaccines within 6 weeks of administration of the study vaccines. Individuals on a tapering dose schedule of oral steroids lasting \\<7 days may be included in the trial as long as they have not received more than one course within the last 2 weeks prior to enrollment.\n* Suspected or known hypersensitivity to any of the investigational or marketed vaccine components.\n* Serious adverse event related to the vaccine (i.e., possible, probably, definite)\n* Persistent inconsolable crying (\\>3 hours) observed after a previous dose.\n* Unable to attend the scheduled visits or comply with the study procedures.\n* Enrolled in another clinical trial involving any therapy.\n* Any condition that in the opinion of the investigator, would pose a health risk to the participant, or interfere with the evaluation of the study objectives.","healthyVolunteers":true,"sex":"ALL","minimumAge":"8 Months","maximumAge":"11 Months","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Seroprotection for Measles 4 Weeks After Vaccination","description":"Seroprotection after measles vaccination was defined as a measles antibody titer ≥ 120 mIU/mL. Measles immunoglobulin G (IgG) antibody was determined using the Enzygnost® Anti-Measles Virus/IgG enzyme-linked immunosorbent assay(ELISA) assay from Siemens, Marburg, Germany.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.6","spread":null},{"groupId":"OG001","value":"91.8","spread":null},{"groupId":"OG002","value":"86.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Seroprotection for Japanese Encephalitis 4 Weeks After Vaccination","description":"Seroprotection after LJEV was defined as at least 1:10 dilution as recommended by the World Health Organization (WHO). JE antibody titers were determined by a plaque reduction neutralization test (PRNT).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":null},{"groupId":"OG001","value":"5.4","spread":null},{"groupId":"OG002","value":"6.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.1","spread":null},{"groupId":"OG001","value":"90.5","spread":null},{"groupId":"OG002","value":"90.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Concentration (GMC) of Measles Antibodies After Vaccination","description":"Measured using the Enzygnost® Anti-Measles Virus/IgG ELISA assay from Siemens, Marburg, Germany.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.8","spread":null},{"groupId":"OG001","value":"7.4","spread":null},{"groupId":"OG002","value":"7.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"318.9","spread":null},{"groupId":"OG001","value":"301.9","spread":null},{"groupId":"OG002","value":"262.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titer (GMT) of Japanese Encephalitis Antibodies After Vaccination","description":"Assayed by plaque reduction neutralization test (PRNT).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.7","spread":null},{"groupId":"OG001","value":"5.7","spread":null},{"groupId":"OG002","value":"5.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"202.8","spread":null},{"groupId":"OG001","value":"155.0","spread":null},{"groupId":"OG002","value":"139.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Experiencing Local and Systemic Reactogenicity After Receiving Live Attenuated Japanese Encephalitis Vaccine (LJEV)","description":"Local reactions included erythema, pain, swelling, or induration. Systemic reactions included loss of appetite, crying, diarrhea, drowsiness, insomnia, irritability, vomiting, or fever. The parents of the participants recorded all local reactions and systemic events on an individual safety diary form.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"53","spread":null},{"groupId":"OG002","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"48","spread":null},{"groupId":"OG002","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null},{"groupId":"OG001","value":"97","spread":null},{"groupId":"OG002","value":"88","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"53","spread":null},{"groupId":"OG002","value":"56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"37","spread":null},{"groupId":"OG002","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"52","spread":null},{"groupId":"OG002","value":"57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"38","spread":null},{"groupId":"OG002","value":"47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"14","spread":null},{"groupId":"OG002","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Experiencing Local and Systemic Reactogenicity After Receiving Measles Vaccine","description":"Local reactions included erythema, pain, swelling, and induration. Systemic reactions included loss of appetite, crying, diarrhea, drowsiness, insomnia, irritability, and vomiting. The parents of the participants recorded all local reactions and systemic events on an individual safety diary form.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"44","spread":null},{"groupId":"OG002","value":"61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"42","spread":null},{"groupId":"OG002","value":"50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"97","spread":null},{"groupId":"OG002","value":"122","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"53","spread":null},{"groupId":"OG002","value":"77","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"37","spread":null},{"groupId":"OG002","value":"42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"52","spread":null},{"groupId":"OG002","value":"64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"38","spread":null},{"groupId":"OG002","value":"52","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"14","spread":null},{"groupId":"OG002","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Experiencing Unsolicited Adverse Events (AE)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"43","spread":null},{"groupId":"OG002","value":"79","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":100},"commonTop":["Upper respiratory tract infection","Acute gastroenteritis","Acute rhinitis","Acute bronchitis","Systemic viral infection"]}}}